The NLRP3 inflammasome in health and disease: The good, the bad and the ugly

Clinical and Experimental Immunology

Volumn 166, Issue 1, 2011, Pages 1-15

  Menu, Philippe ^a   Vince, James E ^a,b  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Infections; Inflammasome; Innate immunity; Interleukin 1; NLRP3

Indexed keywords

ADENOSINE TRIPHOSPHATE; CANAKINUMAB; CORTICOSTEROID; CRYOPYRIN; DIMETHYLBENZ[A]ANTHRACENE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLAMMASOME; INTERLEUKIN 1 DERIVATIVE; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PHORBOL 13 ACETATE 12 MYRISTATE; REACTIVE OXYGEN METABOLITE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 1ALPHA; RECOMBINANT INTERLEUKIN 1BETA; RILONACEPT; X LINKED INHIBITOR OF APOPTOSIS;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ADULT ONSET STILL DISEASE; ANTISYNTHETASE SYNDROME; AUTOINFLAMMATORY DISEASE; BEHCET DISEASE; BIOLOGICAL ACTIVITY; CATALYSIS; CINCA SYNDROME; CLINICAL FEATURE; DRUG HALF LIFE; DRUG SAFETY; ENZYME ACTIVATION; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; GOUT; HUMAN; HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME; IMMUNE RESPONSE; INFECTION; INFECTION CONTROL; INFLAMMATORY DISEASE; INJECTION SITE REACTION; INNATE IMMUNITY; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY CARCINOMA; LOADING DRUG DOSE; MELANOMA; MUCKLE WELLS SYNDROME; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY CANCER; PATHOGENESIS; PATHOGENICITY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; RELAPSING POLYCHONDRITIS; REVIEW; RHEUMATOID ARTHRITIS; SCHNITZLER SYNDROME; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME; UPPER RESPIRATORY TRACT INFECTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BACTERIAL INFECTIONS; CARRIER PROTEINS; CASPASE 1; DIABETES MELLITUS, TYPE 2; ENZYME ACTIVATION; ENZYME PRECURSORS; GENE EXPRESSION REGULATION; GOUT; HEREDITARY AUTOINFLAMMATORY DISEASES; HUMANS; IMMUNITY, INNATE; INFLAMMASOMES; INFLAMMATION; INTERLEUKIN-1BETA; MICE; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; MYCOSES; NEOPLASMS; SIGNAL TRANSDUCTION; VIRUS DISEASES;

EID: 80052626087     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2011.04440.x     Document Type: Review

References (196)

1. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002; 10:417-26.
2. Thornberry NA, Bull HG, Calaycay JR etal. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature 1992; 356:768-74.
3. Dinarello CA. IL-1: discoveries, controversies and future directions. Eur J Immunol 2010; 40:599-606.
4. Veltri S, Smith JW II. Interleukin 1 trials in cancer patients: a review of the toxicity, antitumor and hematopoietic effects. Stem Cells 1996; 14:164-76.
5. Ting JP, Lovering RC, Alnemri ES etal. The NLR gene family: a standard nomenclature. Immunity 2008; 28:285-7.
6. Schroder K, Tschopp J. The inflammasomes. Cell 2010; 140:821-32.
7. Poyet JL, Srinivasula SM, Tnani M, Razmara M, Fernandes-Alnemri T, Alnemri ES. Identification of Ipaf, a human caspase-1-activating protein related to Apaf-1. J Biol Chem 2001; 276:28309-13.
8. Faustin B, Lartigue L, Bruey J-M etal. Reconstituted NALP1 inflammasome reveals two-step mechanism of caspase-1 activation. Mol Cell 2007; 25:713-24.
9. Duncan JA, Bergstralh DT, Wang Y etal. Cryopyrin/NALP3 binds ATP/dATP, is an ATPase, and requires ATP binding to mediate inflammatory signaling. Proc Natl Acad Sci USA 2007; 104:8041-6.
10. Guarda G, Zenger M, Yazdi AS etal. Differential expression of NLRP3 among hematopoietic cells. J Immunol 2011; 186:2529-34.
11. Keller M, Ruegg A, Werner S, Beer HD. Active caspase-1 is a regulator of unconventional protein secretion. Cell 2008; 132:818-31.
12. Luthi AU, Cullen SP, McNeela EA etal. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 2009; 31:84-98.
13. Stehlik C. Multiple interleukin-1beta-converting enzymes contribute to inflammatory arthritis. Arthritis Rheum 2009; 60:3524-30.
14. Miwa K, Asano M, Horai R, Iwakura Y, Nagata S, Suda T. Caspase 1-independent IL-1beta release and inflammation induced by the apoptosis inducer Fas ligand. Nat Med 1998; 4:1287-92.
15. Joosten LA, Netea MG, Fantuzzi G etal. Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1beta. Arthritis Rheum 2009; 60:3651-62.
16. Guma M, Ronacher L, Liu-Bryan R, Takai S, Karin M, Corr M. Caspase 1-independent activation of interleukin-1beta in neutrophil-predominant inflammation. Arthritis Rheum 2009; 60:3642-50.
17. Mayer-Barber KD, Barber DL, Shenderov K etal. Caspase-1 independent IL-1beta production is critical for host resistance to mycobacterium tuberculosis and does not require TLR signaling in vivo. J Immunol 2010; 184:3326-30.
18. Narayan S, Pazar B, Ea HK etal. Octacalcium phosphate (OCP) crystals induce inflammation in vivo through IL-1 but independent of the NLRP3 inflammasome. Arthritis Rheum 2011; 63:422-33.
19. Fantuzzi G, Ku G, Harding MW etal. Response to local inflammation of IL-1 beta-converting enzyme-deficient mice. J Immunol 1997; 158:1818-24.
20. Franchi L, Eigenbrod T, Munoz-Planillo R, Nunez G. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol 2009; 10:241-7.
21. Roberts TL, Idris A, Dunn JA etal. HIN-200 proteins regulate caspase activation in response to foreign cytoplasmic DNA. Science 2009; 323:1057-60.
22. Fernandes-Alnemri T, Yu J-W, Datta P, Wu J, Alnemri ES. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 2009; 458:509-13.
23. Hornung V, Ablasser A, Charrel-Dennis M etal. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 2009; 458:514-18.
24. Poeck H, Bscheider M, Gross O etal. Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin 1 beta production. Nat Immunol 2009; 11:63-9.
25. Pétrilli V, Papin S, Dostert C, Mayor A, Martinon F, Tschopp J. Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ 2007; 14:1583-9.
26. Martinon F. Signaling by ROS drives inflammasome activation. Eur J Immunol 2010; 40:616-19.
27. Hornung V, Latz E. Critical functions of priming and lysosomal damage for NLRP3 activation. Eur J Immunol 2010; 40:620-3.
28. Halle A, Hornung V, Petzold GC etal. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol 2008; 9:857-65.
29. Hornung V, Bauernfeind F, Halle A etal. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 2008; 9:847-56.
30. Dostert C, Guarda G, Romero JF etal. Malarial hemozoin is a Nalp3 inflammasome activating danger signal. PLoS One 2009; 4:e6510.
31. Meissner F, Molawi K, Zychlinsky A. Superoxide dismutase 1 regulates caspase-1 and endotoxic shock. Nat Immunol 2008; 9:866-72.
32. van de Veerdonk FL, Smeekens SP, Joosten LA etal. Reactive oxygen species-independent activation of the IL-1beta inflammasome in cells from patients with chronic granulomatous disease. Proc Natl Acad Sci USA 2010; 107:3030-3.
33. Meissner F, Seger RA, Moshous D, Fischer A, Reichenbach J, Zychlinsky A. Inflammasome activation in NADPH oxidase defective mononuclear phagocytes from patients with chronic granulomatous disease. Blood 2010; 116:1570-3.
34. Zhou R, Yazdi AS, Menu P, Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature 2011; 469:221-5.
35. Bulua AC, Simon A, Maddipati R etal. Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). J Exp Med 2011; 208:519-33.
36. Taxman DJ, Huang MT, Ting JP. Inflammasome inhibition as a pathogenic stealth mechanism. Cell Host Microbe 2010; 8:7-11.
37. Ma Y, Thornton S, Boivin GP, Hirsh D, Hirsch R, Hirsch E. Altered susceptibility to collagen-induced arthritis in transgenic mice with aberrant expression of interleukin-1 receptor antagonist. Arthritis Rheum 1998; 41:1798-805.
38. Horai R, Saijo S, Tanioka H etal. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 2000; 191:313-20.
39. Nicklin MJ, Hughes DE, Barton JL, Ure JM, Duff GW. Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene. J Exp Med 2000; 191:303-12.
40. Chae JJ, Komarow HD, Cheng J etal. Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis. Mol Cell 2003; 11:591-604.
41. Stehlik C, Dorfleutner A. COPs and POPs: modulators of inflammasome activity. J Immunol 2007; 179:7993-8.
42. Masters SL, Mielke LA, Cornish AL etal. Regulation of interleukin-1beta by interferon-gamma is species specific, limited by suppressor of cytokine signalling 1 and influences interleukin-17 production. EMBO Rep 2010; 11:640-6.
43. Saitoh T, Fujita N, Jang MH etal. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature 2008; 456:264-8.
44. Guarda G, Dostert C, Staehli F etal. T cells dampen innate immune responses through inhibition of NLRP1 and NLRP3 inflammasomes. Nature 2009; 460:269-73.
45. Guarda G, Braun M, Staehli F etal. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 2011; 34:213-23.
46. Aganna E, Martinon F, Hawkins PN etal. Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum 2002; 46:2445-52.
47. Hoffman HM. Therapy of autoinflammatory syndromes. J Allergy Clin Immunol 2009; 124:1129-38; quiz 39-40.
48. Neven B, Prieur A-M, Quartier dit Maire P. Medscape, cryopyrinopathies: update on pathogenesis and treatment. Nat Clin Pract Rheumatol 2008; 4:481-9.
49. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004; 20:319-25.
50. Masters SL, Simon A, Aksentijevich I, Kastner DL. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*). Annu Rev Immunol 2009; 27:621-68.
51. Hawkins PN, Lachmann HJ, Aganna E, Mcdermott MF. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 2004; 50:607-12.
52. Hawkins PN, Lachmann HJ, McDermott MF. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med 2003; 348:2583-4.
53. Cook GP, Savic S, Wittmann M, Mcdermott MF. The NLRP3 inflammasome, a target for therapy in diverse disease states. Eur J Immunol 2010; 40:631-4.
54. Goldbach-Mansky R, Dailey NJ, Canna SW etal. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 2006; 355:581-92.
55. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009; 27:519-50.
56. Fisher CJ Jr, Opal SM, Lowry SF etal. Role of interleukin-1 and the therapeutic potential of interleukin-1 receptor antagonist in sepsis. Circ Shock 1994; 44:1-8.
57. Fisher CJ Jr, Dhainaut JF, Opal SM etal. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994; 271:1836-43.
58. Opal SM, Fisher CJ, Jr, Dhainaut JF etal. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 1997; 25:1115-24.
59. Vincent JL, Slotman G, Van Leeuwen PA etal. IL-1ra administration does not improve cardiac function in patients with severe sepsis. J Crit Care 1999; 14:69-72.
60. Fleischmann RM, Tesser J, Schiff MH etal. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65:1006-12.
61. Nuki G, Bresnihan B, Bear MB, McCabe D, Investigators EGOC. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46:2838-46.
62. Hoffman HM, Throne ML, Amar NJ etal. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 2008; 58:2443-52.
63. Goldbach-Mansky R, Shroff SD, Wilson M etal. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum 2008; 58:2432-42.
64. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB etal., Group CiCS. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009; 360:2416-25.
65. Chitkara P, Stojanov S, Kastner DL. The hereditary autoinflammatory syndromes. Pediatr Infect Dis J 2007; 26:353-4.
66. McDermott M, Tschopp J. From inflammasomes to fevers, crystals and hypertension: how basic research explains inflammatory diseases. Trends Mol Med 2007; 13:381-8.
67. Gattorno M, Federici S, Pelagatti MA etal. Diagnosis and management of autoinflammatory diseases in childhood. J Clin Immunol 2008; 28 (Suppl. 1):S73-83.
68. Lindor NM, Arsenault TM, Solomon H, Seidman CE, McEvoy MT. A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome. Mayo Clin Proc 1997; 72:611-15.
69. Wise CA, Bennett LB, Pascual V, Gillum JD, Bowcock AM. Localization of a gene for familial recurrent arthritis. Arthritis Rheum 2000; 43:2041-5.
70. Papin S, Cuenin S, Agostini L etal. The SPRY domain of Pyrin, mutated in familial Mediterranean fever patients, interacts with inflammasome components and inhibits proIL-1beta processing. Cell Death Differ 2007; 14:1457-66.
71. Shoham NG, Centola M, Mansfield E etal. Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Natl Acad Sci USA 2003; 100:13501-6.
72. Brenner M, Ruzicka T, Plewig G, Thomas P, Herzer P. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol 2009; 161:1199-201.
73. Belkhir R, Moulonguet-Doleris L, Hachulla E, Prinseau J, Baglin A, Hanslik T. Treatment of familial Mediterranean fever with anakinra. Ann Intern Med 2007; 146:825-6.
74. Dierselhuis MP, Frenkel J, Wulffraat NM, Boelens JJ. Anakinra for flares of pyogenic arthritis in PAPA syndrome. Rheumatology 2005; 44:406-8.
75. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011; 11:98-107.
76. Schroder K, Zhou R, Tschopp J. The NLRP3 inflammasome: a sensor for metabolic danger? Science 2010; 327:296-300.
77. So A. Developments in the scientific and clinical understanding of gout. Arthritis Res Ther 2008; 10:221.
78. Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440:237-41.
79. So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007; 9:R28.
80. Terkeltaub R, Sundy JS, Schumacher HR etal. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis 2009; 68:1613-17.
81. Sundy JS. Progress in the pharmacotherapy of gout. Curr Opin Rheumatol 2010; 22:188-93.
82. Dinarello CA, Donath MY, Mandrup-Poulsen T. Role of IL-1beta in type 2 diabetes. Curr Opin Endocrinol Diabetes Obes 2010; 17:314-21.
83. Maedler K, Sergeev P, Ehses JA etal. Leptin modulates beta cell expression of IL-1 receptor antagonist and release of IL-1beta in human islets. Proc Natl Acad Sci USA 2004; 101:8138-43.
84. Maedler K, Sergeev P, Ris F etal. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002; 110:851-60.
85. Larsen CM, Faulenbach M, Vaag A etal. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356:1517-26.
86. Wen H, Gris D, Lei Y etal. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol 2011; 12:408-15.
87. Masters SL, Dunne A, Subramanian SL etal. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes. Nat Immunol 2010; 11:897-904.
88. Stienstra R, Joosten LAB, Koenen T etal. The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab 2010; 12:593-605.
89. Vandanmagsar B, Youm Y-H, Ravussin A etal. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 2011; 17:179-88.
90. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315:1650-9.
91. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357:539-45.
92. Nakamura S, Kashimoto S, Kajikawa F, Nakata K. Combination effect of recombinant human interleukin 1 alpha with antitumor drugs on syngeneic tumors in mice. Cancer Res 1991; 51:215-21.
93. Onozaki K, Matsushima K, Aggarwal BB, Oppenheim JJ. Human interleukin 1 is a cytocidal factor for several tumor cell lines. J Immunol 1985; 135:3962-8.
94. Nakamura S, Nakata K, Kashimoto S, Yoshida H, Yamada M. Antitumor effect of recombinant human interleukin 1 alpha against murine syngeneic tumors. Jpn J Cancer Res 1986; 77:767-73.
95. Murphy JE, Morales RE, Scott J, Kupper TS. IL-1 alpha, innate immunity, and skin carcinogenesis: the effect of constitutive expression of IL-1 alpha in epidermis on chemical carcinogenesis. J Immunol 2003; 170:5697-703.
96. Ghiringhelli F, Apetoh L, Tesniere A etal. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009; 15:1170-8.
97. Siegmund B, Lehr HA, Fantuzzi G, Dinarello CA. IL-1 beta-converting enzyme (caspase-1) in intestinal inflammation. Proc Natl Acad Sci USA 2001; 98:13249-54.
98. Bauer C, Duewell P, Mayer C etal. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut 2010; 59:1192-9.
99. Hirota SA, Ng J, Lueng A etal. NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis. Inflamm Bowel Dis 2010; 17:1359-72.
100. Zaki MH, Boyd KL, Vogel P, Kastan MB, Lamkanfi M, Kanneganti TD. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity 2010; 32:379-91.
101. Dupaul-Chicoine J, Yeretssian G, Doiron K etal. Control of intestinal homeostasis, colitis, and colitis-associated colorectal cancer by the inflammatory caspases. Immunity 2010; 32:367-78.
102. Zaki MH, Vogel P, Body-Malapel M, Lamkanfi M, Kanneganti TD. IL-18 production downstream of the Nlrp3 inflammasome confers protection against colorectal tumor formation. J Immunol 2010; 185:4912-20.
103. Allen IC, TeKippe EM, Woodford RM etal. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med 2010; 207:1045-56.
104. Hu B, Elinav E, Huber S etal. Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc Natl Acad Sci USA 2010; 107:21635-40.
105. Rakoff-Nahoum S, Medzhitov R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 2007; 317:124-7.
106. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004; 118:229-41.
107. Araki A, Kanai T, Ishikura T etal. MyD88-deficient mice develop severe intestinal inflammation in dextran sodium sulfate colitis. J Gastroenterol 2005; 40:16-23.
108. Villani AC, Lemire M, Fortin G etal. Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. Nat Genet 2009; 41:71-6.
109. Apte RN, Voronov E. Interleukin-1 - a major pleiotropic cytokine in tumor-host interactions. Semin Cancer Biol 2002; 12:277-90.
110. Okamoto M, Liu W, Luo Y etal. Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1beta. J Biol Chem 2010; 285:6477-88.
111. Portier M, Zhang XG, Ursule E etal. Cytokine gene expression in human multiple myeloma. Br J Haematol 1993; 85:514-20.
112. Rambaldi A, Torcia M, Bettoni S etal. Modulation of cell proliferation and cytokine production in acute myeloblastic leukemia by interleukin-1 receptor antagonist and lack of its expression by leukemic cells. Blood 1991; 78:3248-53.
113. Demetri GD, Ernst TJ, Pratt ES, 2nd, Zenzie BW, Rheinwald JG, Griffin JD. Expression of ras oncogenes in cultured human cells alters the transcriptional and posttranscriptional regulation of cytokine genes. J Clin Invest 1990; 86:1261-9.
114. Lewis AM, Varghese S, Xu H, Alexander HR. Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J Transl Med 2006; 4:48.
115. Saijo Y, Tanaka M, Miki M etal. Proinflammatory cytokine IL-1 beta promotes tumor growth of Lewis lung carcinoma by induction of angiogenic factors: in vivo analysis of tumor-stromal interaction. J Immunol 2002; 169:469-75.
116. Voronov E, Shouval DS, Krelin Y etal. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA 2003; 100:2645-50.
117. Vidal-Vanaclocha F, Amezaga C, Asumendi A, Kaplanski G, Dinarello CA. Interleukin-1 receptor blockade reduces the number and size of murine B16 melanoma hepatic metastases. Cancer Res 1994; 54:2667-72.
118. Krelin Y, Voronov E, Dotan S etal. Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. Cancer Res 2007; 67:1062-71.
119. Vidal-Vanaclocha F, Fantuzzi G, Mendoza L etal. IL-18 regulates IL-1beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. Proc Natl Acad Sci USA 2000; 97:734-9.
120. Stosic-Grujicic S, Basara N, Dinarello CA. Modulatory in vitro effects of interleukin-1 receptor antagonist (IL-1Ra) or antisense oligonucleotide to interleukin-1 beta converting enzyme (ICE) on acute myeloid leukaemia (AML) cell growth. Clin Lab Haematol 1999; 21:173-85.
121. Delwel R, van Buitenen C, Salem M etal. Interleukin-1 stimulates proliferation of acute myeloblastic leukemia cells by induction of granulocyte-macrophage colony-stimulating factor release. Blood 1989; 74:586-93.
122. Rodriguez-Cimadevilla JC, Beauchemin V, Villeneuve L, Letendre F, Shaw A, Hoang T. Coordinate secretion of interleukin-1 beta and granulocyte-macrophage colony-stimulating factor by the blast cells of acute myeloblastic leukemia: role of interleukin-1 as an endogenous inducer. Blood 1990; 76:1481-9.
123. Cozzolino F, Rubartelli A, Aldinucci D etal. Interleukin 1 as an autocrine growth factor for acute myeloid leukemia cells. Proc Natl Acad Sci USA 1989; 86:2369-73.
124. Bernstein SH, Fay J, Frankel S etal. A phase I study of recombinant human soluble interleukin-1 receptor (rhu IL-1R) in patients with relapsed and refractory acute myeloid leukemia. Cancer Chemother Pharmacol 1999; 43:141-4.
125. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
126. El-Omar EM, Carrington M, Chow WH etal. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404:398-402.
127. Perri F, Terracciano F, Gentile M, Merla A, Scimeca D, Zullo A. Role of interleukin polymorphisms in gastric cancer: 'pros and cons'. World J Gastrointest Oncol 2010; 2:265-71.
128. Tu S, Bhagat G, Cui G etal. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 2008; 14:408-19.
129. Lust JA, Lacy MQ, Zeldenrust SR etal. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc 2009; 84:114-22.
130. Dinarello CA. Why not treat human cancer with interleukin-1 blockade? Cancer Metastasis Rev 2010; 29:317-29.
131. Cassel SL, Eisenbarth SC, Iyer SS etal. The Nalp3 inflammasome is essential for the development of silicosis. Proc Natl Acad Sci USA 2008; 105:9035-40.
132. Dostert C, Pétrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 2008; 320:674-7.
133. Watanabe H, Gaide O, Pétrilli V etal. Activation of the IL-1beta-processing inflammasome is involved in contact hypersensitivity. J Invest Dermatol 2007; 127:1956-63.
134. Feldmeyer L, Keller M, Niklaus G, Hohl D, Werner S, Beer H-D. The inflammasome mediates UVB-induced activation and secretion of interleukin-1beta by keratinocytes. Curr Biol 2007; 17:1140-5.
135. Sutterwala FS, Ogura Y, Szczepanik M etal. Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 2006; 24:317-27.
136. Shio MT, Tiemi Shio M, Eisenbarth SC etal. Malarial hemozoin activates the NLRP3 inflammasome through Lyn and Syk kinases. PLoS Pathog 2009; 5:e1000559.
137. Omi T, Kumada M, Kamesaki T etal. An intronic variable number of tandem repeat polymorphisms of the cold-induced autoinflammatory syndrome 1 (CIAS1) gene modifies gene expression and is associated with essential hypertension. Eur J Hum Genet 2006; 14:1295-305.
138. Ritter M, Gross O, Kays S etal. Schistosoma mansoni triggers Dectin-2, which activates the Nlrp3 inflammasome and alters adaptive immune responses. Proc Natl Acad Sci USA 2010; 107:20459-64.
139. Koo IC, Wang C, Raghavan S, Morisaki JH, Cox JS, Brown EJ. ESX-1-dependent cytolysis in lysosome secretion and inflammasome activation during mycobacterial infection. Cell Microbiol 2008; 10:1866-78.
140. Master SS, Rampini SK, Davis AS etal. Mycobacterium tuberculosis prevents inflammasome activation. Cell Host Microbe 2008; 3:224-32.
141. Mishra BB, Moura-Alves P, Sonawane A etal. Mycobacterium tuberculosis protein ESAT-6 is a potent activator of the NLRP3/ASC inflammasome. Cell Microbiol 2010; 12:1046-63.
142. Walter K, Holscher C, Tschopp J, Ehlers S. NALP3 is not necessary for early protection against experimental tuberculosis. Immunobiology 2010; 215:804-11.
143. Kafka D, Ling E, Feldman G etal. Contribution of IL-1 to resistance to Streptococcus pneumoniae infection. Int Immunol 2008; 20:1139-46.
144. McNeela EA, Burke A, Neill DR etal. Pneumolysin activates the NLRP3 inflammasome and promotes proinflammatory cytokines independently of TLR4. PLoS Pathog 2010; 6:e1001191.
145. Harder J, Franchi L, Munoz-Planillo R, Park JH, Reimer T, Nunez G. Activation of the Nlrp3 inflammasome by Streptococcus pyogenes requires streptolysin O and NF-kappa B activation but proceeds independently of TLR signaling and P2X7 receptor. J Immunol 2009; 183:5823-9.
146. Mariathasan S, Weiss DS, Newton K etal. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 2006; 440:228-32.
147. Willingham SB, Allen IC, Bergstralh DT etal. NLRP3 (NALP3, Cryopyrin) facilitates in vivo caspase-1 activation, necrosis, and HMGB1 release via inflammasome-dependent and -independent pathways. J Immunol 2009; 183:2008-15.
148. He X, Mekasha S, Mavrogiorgos N, Fitzgerald KA, Lien E, Ingalls RR. Inflammation and fibrosis during Chlamydia pneumoniae infection is regulated by IL-1 and the NLRP3/ASC inflammasome. J Immunol 2010; 184:5743-54.
149. Broz P, Newton K, Lamkanfi M, Mariathasan S, Dixit VM, Monack DM. Redundant roles for inflammasome receptors NLRP3 and NLRC4 in host defense against Salmonella. J Exp Med 2010; 207:1745-55.
150. Franchi L, Amer A, Body-Malapel M etal. Cytosolic flagellin requires Ipaf for activation of caspase-1 and interleukin 1beta in salmonella-infected macrophages. Nat Immunol 2006; 7:576-82.
151. Fernandes-Alnemri T, Yu J-W, Juliana C etal. The AIM2 inflammasome is critical for innate immunity to Francisella tularensis. Nat Immunol 2010; 11:385-93.
152. Jones JW, Kayagaki N, Broz P etal. Absent in melanoma 2 is required for innate immune recognition of Francisella tularensis. Proc Natl Acad Sci USA 2010; 107:9771-6.
153. Amer A, Franchi L, Kanneganti T-D etal. Regulation of Legionella phagosome maturation and infection through flagellin and host Ipaf. J Biol Chem 2006; 281:35217-23.
154. Warren SE, Armstrong A, Hamilton MK etal. Cutting edge: cytosolic bacterial DNA activates the inflammasome via Aim2. J Immunol 2010; 185:818-21.
155. Rathinam VAK, Jiang Z, Waggoner SN etal. The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat Immunol 2010; 11:395-402.
156. Sutterwala FS, Mijares LA, Li L, Ogura Y, Kazmierczak BI, Flavell RA. Immune recognition of Pseudomonas aeruginosa mediated by the IPAF/NLRC4 inflammasome. J Exp Med 2007; 204:3235-45.
157. Miao EA, Mao DP, Yudkovsky N etal. Innate immune detection of the type III secretion apparatus through the NLRC4 inflammasome. Proc Natl Acad Sci USA 2010; 107:3076-80.
158. Franchi L, Stoolman J, Kanneganti T-D, Verma A, Ramphal R, Núñez G. Critical role for Ipaf in Pseudomonas aeruginosa-induced caspase-1 activation. Eur J Immunol 2007; 37:3030-9.
159. Suzuki T, Franchi L, Toma C etal. Differential regulation of caspase-1 activation, pyroptosis, and autophagy via Ipaf and ASC in Shigella-infected macrophages. PLoS Pathog 2007; 3:e111.
160. Duncan JA, Gao X, Huang MT etal. Neisseria gonorrhoeae activates the proteinase cathepsin B to mediate the signaling activities of the NLRP3 and ASC-containing inflammasome. J Immunol 2009; 182:6460-9.
161. Shimada T, Park BG, Wolf AJ etal. Staphylococcus aureus evades lysozyme-based peptidoglycan digestion that links phagocytosis, inflammasome activation, and IL-1beta secretion. Cell Host Microbe 2010; 7:38-49.
162. Miller LS, Pietras EM, Uricchio LH etal. Inflammasome-mediated production of IL-1beta is required for neutrophil recruitment against Staphylococcus aureus in vivo. J Immunol 2007; 179:6933-42.
163. Miller LS, O'Connell RM, Gutierrez MA etal. MyD88 mediates neutrophil recruitment initiated by IL-1R but not TLR2 activation in immunity against Staphylococcus aureus. Immunity 2006; 24:79-91.
164. Hultgren OH, Svensson L, Tarkowski A. Critical role of signaling through IL-1 receptor for development of arthritis and sepsis during Staphylococcus aureus infection. J Immunol 2002; 168:5207-12.
165. Craven RR, Gao X, Allen IC etal. Staphylococcus aureus alpha-hemolysin activates the NLRP3-inflammasome in human and mouse monocytic cells. PLoS One 2009; 4:e7446.
166. Toma C, Higa N, Koizumi Y etal. Pathogenic Vibrio activate NLRP3 inflammasome via cytotoxins and TLR/nucleotide-binding oligomerization domain-mediated NF-kappa B signaling. J Immunol 2010; 184:5287-97.
167. Boyden ED, Dietrich WF. Nalp1b controls mouse macrophage susceptibility to anthrax lethal toxin. Nat Genet 2006; 38:240-4.
168. Hsu L-C, Ali SR, McGillivray S etal. A NOD2-NALP1 complex mediates caspase-1-dependent IL-1beta secretion in response to Bacillus anthracis infection and muramyl dipeptide. Proc Natl Acad Sci USA 2008; 105:7803-8.
169. Moayeri M, Crown D, Newman ZL etal. Inflammasome sensor Nlrp1b-dependent resistance to anthrax is mediated by caspase-1, IL-1 signaling and neutrophil recruitment. PLoS Pathog 2010; 6:e1001222.
170. Terra JK, Cote CK, France B etal. Cutting edge: resistance to Bacillus anthracis infection mediated by a lethal toxin sensitive allele of Nalp1b/Nlrp1b. J Immunol 2010; 184:17-20.
171. Abdul-Sater AA, Koo E, Hacker G, Ojcius DM. Inflammasome-dependent caspase-1 activation in cervical epithelial cells stimulates growth of the intracellular pathogen Chlamydia trachomatis. J Biol Chem 2009; 284:26789-96.
172. Witola WH, Mui E, Hargrave A etal. NALP1 influences susceptibility to human congenital toxoplasmosis, proinflammatory cytokine response, and fate of Toxoplasma gondii-infected monocytic cells. Infect Immun 2011; 79:756-66.
173. Griffith JW, Sun T, McIntosh MT, Bucala R. Pure Hemozoin is inflammatory in vivo and activates the NALP3 inflammasome via release of uric acid. J Immunol 2009; 183:5208-20.
174. Gross O, Poeck H, Bscheider M etal. Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence. Nature 2009; 459:433-6.
175. Said-Sadier N, Padilla E, Langsley G, Ojcius DM. Aspergillus fumigatus stimulates the NLRP3 inflammasome through a pathway requiring ROS production and the Syk tyrosine kinase. PLoS One 2010; 5:e10008.
176. Kumar H, Kumagai Y, Tsuchida T etal. Involvement of the NLRP3 inflammasome in innate and humoral adaptive immune responses to fungal beta-glucan. J Immunol 2009; 183:8061-7.
177. Kanneganti TD, Body-Malapel M, Amer A etal. Critical role for Cryopyrin/Nalp3 in activation of caspase-1 in response to viral infection and double-stranded RNA. J Biol Chem 2006; 281:36560-8.
178. Allen IC, Scull MA, Moore CB etal. The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA. Immunity 2009; 30:556-65.
179. Thomas PG, Dash P, Aldridge JR etal. The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1. Immunity 2009; 30:566-75.
180. Ichinohe T, Lee HK, Ogura Y, Flavell R, Iwasaki A. Inflammasome recognition of influenza virus is essential for adaptive immune responses. J Exp Med 2009; 206:79-87.
181. Ichinohe T, Pang IK, Iwasaki A. Influenza virus activates inflammasomes via its intracellular M2 ion channel. Nat Immunol 2010; 11:404-10.
182. Muruve DA, Pétrilli V, Zaiss AK etal. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature 2008; 452:103-7.
183. Rajan JV, Rodriguez D, Miao EA, Aderem A. The NLRP3 inflammasome detects EMCV and VSV infection. J Virol 2011; 85:4167-72.
184. Reimer T, Shaw MH, Franchi L etal. Experimental cerebral malaria progresses independently of the Nlrp3 inflammasome. Eur J Immunol 2010; 40:764-9.
185. Rigante D, Ansuini V, Bertoni B etal. Treatment with anakinra in the hyperimmunoglobulinemia D/periodic fever syndrome. Rheumatol Int 2006; 27:97-100.
186. Lequerré T, Vittecoq O, Pouplin S etal. Mevalonate kinase deficiency syndrome with structural damage responsive to anakinra. Rheumatology 2007; 46:1860-2.
187. Cailliez M, Garaix F, Rousset-Rouvière C etal. Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisis. J Inherit Metab Dis 2006; 29:763.
188. Simon A, Bodar EJ, van der Hilst JCH etal. Beneficial response to interleukin 1 receptor antagonist in traps. Am J Med 2004; 117:208-10.
189. Kalliolias GD, Liossis S-NC. The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis. Exp Opin Invest Drugs 2008; 17:349-59.
190. Wendling D, Govindaraju S, Prati C, Toussirot E, Bertolini E. Efficacy of anakinra in a patient with refractory relapsing polychondritis. Joint Bone Spine 2008; 75:622-4.
191. Vounotrypidis P, Sakellariou GT, Zisopoulos D, Berberidis C. Refractory relapsing polychondritis: rapid and sustained response in the treatment with an IL-1 receptor antagonist (anakinra). Rheumatology 2006; 45:491-2.
192. Pizzirani C, Falzoni S, Govoni M etal. Dysfunctional inflammasome in Schnitzler's syndrome. Rheumatology 2009; 48:1304-8.
193. Delluc A, Limal N, Puéchal X, Francès C, Piette JC, Cacoub P. Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome. Ann Rheum Dis 2008; 67:278-9.
194. Bilginer Y, Ayaz NA, Ozen S. Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet's disease. Clin Rheumatol 2010; 29:209-10.
195. Botsios C, Sfriso P, Furlan A, Punzi L, Dinarello CA. Resistant Behçet disease responsive to anakinra. Ann Intern Med 2008; 149:284-6.
196. Furlan A, Botsios C, Ruffatti A, Todesco S, Punzi L. Antisynthetase syndrome with refractory polyarthritis and fever successfully treated with the IL-1 receptor antagonist, anakinra: a case report. Joint Bone Spine 2008; 75:366-7.